Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results

被引：0
|
作者：
Reardon, DA
Quinn, J
Rich, J
Vredenburgh, J
Desjardins, A
Sathornsumetee, S
Salvado, A
Nikolova, Z
Bigner, D
Friedman, H
机构：
[1] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
NEURO-ONCOLOGY | 2005年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
35
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [21] Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme (vol 23, pg 9359, 2005)
    Reardon
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1224 - 1224
  • [22] Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma
    Sathornsumetee, Sith
    Rich, Jeremy N.
    Vredenburgh, James J.
    Desjardins, Annick
    Quinn, Jennifer A.
    Gururangan, Sri
    Friedman, Allan H.
    Egorin, Merrill J.
    Salvado, August
    Friedman, Henry S.
    Reardon, David A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 451 - 451
  • [23] A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.
    Reardon, D.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Sathornsumetee, S.
    Gururangan, S.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 77S - 77S
  • [24] Multicentre phase II study of imatinib mesylate (gleevec) in patients with recurrent glioblastoma: An EORTC NDDG/BTG intergroup study
    van den Bent, M
    Brandes, AA
    van Oosterom, A
    Dittrich, C
    Fumoleau, P
    Coudert, B
    Twelves, C
    de Balincourt, C
    Lacombe, D
    Raymond, E
    NEURO-ONCOLOGY, 2004, 6 (04) : 383 - 384
  • [25] An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma.
    Sathornsumetee, S.
    Reardon, D. A.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Gururangan, S.
    Egorin, M.
    Salvado, A.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 72S - 72S
  • [26] A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Reardon, David A.
    Vredenburgh, James. J.
    Desjardins, Annick
    Janney, Dorothea E.
    Peters, Katherine B.
    Friedman, Allan H.
    Gururangan, Sridharan
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2009, 11 (06) : 946 - 946
  • [27] A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma
    Friedman, H. S.
    Vredenburgh, J. J.
    Desjardins, A.
    Janney, D. E.
    Peters, K. B.
    Friedman, A. H.
    Gururangan, S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma
    Reardon, David A.
    Desjardins, Annick
    Vredenburgh, James J.
    Sathornsumetee, Sith
    Rich, Jeremy N.
    Quinn, Jennifer A.
    Lagattuta, Theodore F.
    Egorin, Merrill J.
    Gururangan, Sridharan
    McLendon, Roger
    Herndon, James E., II
    Friedman, Allan H.
    Salvado, August J.
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2008, 10 (03) : 330 - 340
  • [29] PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS
    Reardon, David A.
    Desjardins, Annick
    Vredenburgh, James J.
    Gururangan, Sridharan
    Peters, Katherine B.
    Norfleet, Julie A.
    Friedman, Allan H.
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2009, 11 (06) : 905 - 905
  • [30] Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results
    Reardon, D.
    Desjardins, A.
    Vredenburgh, J. J.
    Gururangan, S.
    Peters, K. B.
    Norfleet, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345